Nucynta Er Patent Expiration

NUCYNTA ER's oppositions filed in EPO
NUCYNTA ER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6071970 COLLEGIUM PHARM INC Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Jun, 2017

(7 years ago)

USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(1 year, 11 months ago)

US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
Oct, 2022

(1 year, 8 months ago)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(7 months ago)

US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(7 months ago)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(7 months ago)

US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(2 months from now)

US11344512 COLLEGIUM PHARM INC Titration of tapentadol
Apr, 2028

(3 years from now)

US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Sep, 2028

(4 years from now)

Nucynta Er is a drug owned by Collegium Pharmaceutical Inc. It is used for managing severe chronic pain, including neuropathic pain associated with diabetic peripheral neuropathy, when other treatment options are inadequate. Nucynta Er uses Tapentadol Hydrochloride as an active ingredient. Nucynta Er was launched by Collegium Pharm Inc in 2011. It is is available in tablet, extended release form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 22, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Dosage Form(NDF) Aug 25, 2014
New Indication(I-656) Aug 28, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily,...


How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents